Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IHEM17093 / PAC203 / Jane Liesveld

Research Question:
What dose of the study drug, pacritinib, is safest and works best for patients with myelofibrosis?

Basic Study Information

Purpose:
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or to P/C therapy (approximately 116 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03165734?term=PAC203&rank=1
Study Reference #: IHEM17093

Lead Researcher (Principal Investigator)

Lead Researcher:  Jane Liesveld, MD

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Parking:  Reimbursed

Learn More About These Conditions

More information about Myelofibrosis

Return to Search